paroxetine has been researched along with ribavirin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Asnis, GM; De La Garza, R | 1 |
| Hauser, P; Indest, DW; Loftis, JM; Moles, JK; Morasco, BJ; Rifai, MA | 1 |
| Asnis, GM; Borisov, AS; Bruno, CJ; Demetrashvili, MF; Evans, DL; Henderson, MA; Miller, AH; Raison, CL; Reinus, JF; Staab, JP; Weinreib, R; Woolwine, BJ; Zajecka, JM | 1 |
| Demetrashvili, MF; Liu, S; Manatunga, A; McNutt, MD; Miller, AH; Musselman, DL; Raison, CL; Royster, EB; Woolwine, BJ | 1 |
| Hou, XJ; Wang, J; Xu, JH; Yu, YY | 1 |
3 review(s) available for paroxetine and ribavirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.
Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases | 2006 |
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2013 |
3 trial(s) available for paroxetine and ribavirin
| Article | Year |
|---|---|
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Paroxetine; Personality Inventory; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans | 2007 |
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Ribavirin | 2007 |
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Double-Blind Method; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2012 |
9 other study(ies) available for paroxetine and ribavirin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |